Relmada Therapeutics Financials - Benzinga

Relmada Therapeutics Inc

RLMDNASDAQ

Trade with Public

Trade with Public

$4.39

-0.15-3.19%

Last update: Sep 3, 9:48 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Relmada Therapeutics Financials

Relmada Therapeutics (RLMD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Relmada Therapeutics Q2 EPS $(0.11) Beats $(0.20) Estimate

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 45 percent. This is a 63.33 percent increase over losses of $(0.30) per share

Benzinga Newsdesk

PRO
Relmada Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by 10 percent. This is a 62.07 percent increase over losses of $(0.58) per share

Benzinga Newsdesk

Earnings Scheduled For May 12, 2026

Benzinga Insights

PRO
Relmada Therapeutics Q4 EPS $(0.27) Misses $(0.14) Estimate

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.14) by 92.86 percent. This is a 56.45 percent increase over losses of $(0.62) per share

Benzinga Newsdesk

Earnings Scheduled For March 19, 2026

Benzinga Insights

PRO
Relmada Therapeutics Q3 EPS $(0.30) Misses $(0.04) Estimate

Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.04) by 650 percent. This is a 58.33 percent increase over losses of $(0.72) per share

Benzinga Newsdesk